HDT Bio Corp. is a biopharmaceutical company developing drugs for immunotherapy of cancers and infectious diseases. Our products are designed to be cost-effective solutions to unmet medical needs and complementary to existing, cutting-edge immunotherapies.
Location: United States, Washington, Seattle
Employees: 11-50
Total raised: $9.3M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | Zoic Capit... | zoiccapita... |
Funding Rounds 4
| Date | Series | Amount | Investors |
| 11.08.2022 | Grant | $1.8M | - |
| 20.07.2022 | Grant | $1.5M | - |
| 16.02.2021 | - | $3M | Zoic Capit... |
| 06.10.2020 | Seed | $3M | - |
Mentions in press and media 6
| Date | Title | Description |
| 11.08.2022 | Seattle startup HDT Bio lands $1.8M U.S. Army grant to develop nasal spray against viruses | HDT Bio CEO Steve Reed. (HDT Bio Photo) Seattle startup HDT Bio will develop a nasal spray designed to counteract a wide range of respiratory viruses with a nearly $1.8 million grant from the U.S. Army. “We hope to address not only disease ... |
| 16.08.2021 | Covid-19 roundup: Tiny sample size leads FDA to turn down Rigel's EUA; Seattle biotech to co-develop mRNA vaccine in South Korea | Four months after Rigel announced possible Phase II results for its Covid-19 treatment, the FDA has deemed the sample size too small and insufficient for an emergency use authorization, the company announced Friday. The Ph... |
| 17.05.2021 | HDT Bio Awarded $2.9M NIH Grant to Develop RNA Vaccine for HIV-1 | HDT Bio Corp., a developer of immunotherapies for oncology and infectious diseases, announced today the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health (NIH) has awarded the company a three-year... |
| 05.10.2020 | Seattle startup HDT Bio raises $3M to support development of COVID-19 vaccine | Steve Reed, CEO of HDT Bio. (HDT Bio Photo) Seattle-based biotech company HDT Bio closed a seed round totaling roughly $3 million to support work on its COVID-19 vaccine candidate HDT-301. Researchers from HDT Bio and the University of Wash... |
| 05.10.2020 | HDT Bio Completes $3M Seed Financing | HDT Bio Corp., a Seattle, WA-based biotechnology company enabling global access to immunotherapies for oncology and infectious disease, closed its seed financing round totaling ~$3m. The round was co-led by Zoic Capital and joined by angel ... |
| 05.10.2020 | Seattle startup HDT Bio raises $3M to support development of COVID-19 vaccine | [Update 2/16/21: HDT Bio announced an additional $3 million in seed financing, bringing the round, led by Zoic Capital, to $6 million. The funding will support the biotech company’s three key products going into clinical trials this year.] ... |